@article{33ee48bd701d4f70869f125133ef27c2,
title = "The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs",
abstract = "Azacitidine and decitabine are cytosine analogs that function as DNA methyltransferase inhibitors. These agents, commonly referred to as “hypomethylating agents,” are widely used for the treatment of myelodysplastic syndrome and acute myeloid leukemia (AML). In this review, we discuss the clinical development of these drugs, including the early studies that led to the optimization of their doses and schedules, and the pivotal studies that led to their regulatory approval, both as monotherapy and in combination with venetoclax for older adults with AML who are unfit for intensive chemotherapy. We also review the more recent development of oral hypomethylating agent formulations and the novel oral strategies being developed in myelodysplastic syndrome and AML.",
keywords = "Azacitidine, Decitabine, DNA methyltransferase inhibitors, Epigenetics, Venetoclax",
author = "Short, {Nicholas J.} and Herv{\'e} Dombret and Lionel Ad{\`e}s and Kantarjian, {Hagop M}",
note = "Funding Information: Conflicts of Interest and Source of Funding: N.J.S. has served as consultant for Takeda Oncology and AstraZeneca, reports receiving research grants from Takeda Oncology and Astellas Pharma Inc., and has received honoraria from Amgen. H.D. has served as consultant for Pfizer and Daiichi Sankyo; has received research grants from Amgen, Astellas Pharma Inc., Incyte, Jazz Pharmaceuticals, Novartis, Pfizer, and Servier; and has received honoraria from Abbvie, Amgen, BMS-Celgene, Daiichi Sankyo, Incyte, Jazz Pharmaceuticals, and Pfizer. L.A. has served as consultant for Takeda, BMS, Novartis, and Abbvie and has received research grant from BMS. H.K. has received research grants from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, Pfizer, Actinium, and Takeda. N.J.S. is supported by the K12 Paul Calabresi Clinical Oncology Scholar Award and the American Society of Hematology Junior Faculty Scholar Award in Clinical Research. Publisher Copyright: Copyright {\textcopyright} 2022 Wolters Kluwer Health, Inc. All rights reserved.",
year = "2022",
doi = "10.1097/PPO.0000000000000568",
language = "English (US)",
volume = "28",
pages = "29--36",
journal = "Cancer Journal (United States)",
issn = "1528-9117",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "1",
}